

## INFUGEM - (1200MG/120ML, 1300MG/130ML, 1400MG/140ML, 1500MG/150ML, 1600MG/160ML, 1700MG/170ML, 1800MG/180ML, 1900MG/190ML, 2000MG/200ML, 2200MG/220ML - Solution)

<b>Generic Name</b>	GEMCITABINE HYDROCHLORIDE	<b>Innovator</b>	Sun Pharma
<b>Dosage</b>	1200MG/120ML, 1300MG/130ML, 1400MG/140ML, 1500MG/150ML, 1600MG/160ML, 1700MG/170ML, 1800MG/180ML, 1900MG/190ML, 2000MG/200ML, 2200MG/220ML - Solution	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	INFUGEM is a nucleoside metabolic inhibitor indicated: ? in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ? in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ? in combination with cisplatin, for the treatment of non-small cell lung cancer. (1.3) ? as a single agent for the treatment of pancreatic cancer.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.